首页> 外国专利> Producing transgenic mammal comprising reduced expression of DNAse I, useful for studying development of systemic lupus erythematosus and in drug screening

Producing transgenic mammal comprising reduced expression of DNAse I, useful for studying development of systemic lupus erythematosus and in drug screening

机译：生产包含降低的DNAse I表达的转基因哺乳动物，可用于研究系统性红斑狼疮的发展和药物筛选

页面导航

摘要
著录项
相似文献

摘要

Producing, (P), a transgenic, non-human mammal (A) that has at least partial reduction in activity of DNAse I (I), is new. Production of a transgenic, non-human mammal (A) that has at least partial reduction in activity of DNAse I (I), where an embryonal stem cell is transfected with a (I)-targeting vector and stable clones isolated in which the endogenous (I)-encoding gene has been (partially) replaced by other sequences or destroyed, as a result of homologous recombination with parts of the targeting vector. These clones are implanted into a suitably prepared surrogate dam and progeny selected for presence of DNA incorporation. Independent claims are also included for the following: (1) (A) produced by P; (2) recombinant (I)-targeting vector used for homologous recombination; (3) stably transfected cells in which all or part of the (I)-encoding gene has been replaced by another DNA sequence; (4) model system for analysis of either the origins of SLE (systemic lupus erythematosus) or treatments of diseases, specifically SLE, that includes at least one (A); (5) testing new pharmaceuticals for activity against SLE, using (A) or stable cell clones or organs derived from (A); and (6) testing the affects of genetic, biological, chemical and physical factors on development of SLE.

机译：生产（P）至少部分降低了DNAse I（I）活性的转基因非人类哺乳动物（A）是新的。产生至少部分降低DNAse I（I）活性的转基因非人类哺乳动物（A），其中将胚胎干细胞用（I）靶向载体转染，并分离出稳定的克隆，其中内源性（I）编码基因已经（部分）被其他序列取代或被破坏，这是由于与目标载体部分进行了同源重组的结果。将这些克隆植入适当制备的替代坝中，并根据DNA掺入情况选择后代。还包括以下方面的独立权利要求：（1）（A）由P提出; （2）用于同源重组的重组（I）-靶向载体; （3）稳定转染的细胞，其中（I）编码基因的全部或部分已被另一DNA序列取代; （4）用于分析系统性红斑狼疮（系统性红斑狼疮）起源或疾病治疗的模型系统，特别是系统性红斑狼疮，包括至少一个（A）; （5）使用（A）或衍生自（A）的稳定细胞克隆或器官测试新药对SLE的活性; （6）检验遗传，生物学，化学和物理因素对SLE发展的影响。

著录项

公开/公告号DE10025855A1

专利类型
公开/公告日2001-12-06

原文格式PDF
申请/专利权人 MOEROEY TARIK;ZEVNIK BRANKO;KARSUNKY HOLGER;MANNHERZ HANS-GEORG;NAPIREI MARKUS;STEPHAN HARALD;
展开▼

申请/专利号DE2000125855
发明设计人 MANNHERZ HANS-GEORG;KARSUNKY HOLGER;NAPIREI MARKUS;MOEROEY TARIK;ZEVNIK BRANKO;STEPHAN HARALD;
展开▼

申请日2000-05-25
分类号A01K67/027;C12N9/14;
国家 DE
入库时间 2022-08-22 00:27:43

相似文献

专利
外文文献
中文文献